Published in Lab Business Week, January 30th, 2005
Contributing to the current period loss are the company's expenditures related to ongoing clinical development programs and a $2.7 million non-cash charge for the issuance of common stock to the Ciblex Corporation in connection with the MIF technology.
The company's operating expenditures were partially offset by revenues from government research grants and license agreements.
Research and development...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.